Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

Inclusion * Patients must have undergone a matched related donor, matched unrelated donor or cord blood Hematopoietic Stem Cell Transplant (HSCT) over 6 months ago * Patients currently on Desferal (desferrioxamine) therapy will require a one day wash out prior to the first dose of study drug * Serum ferritin \>= 1500 ng/mL on two occasions two weeks apart at screening; samples must be obtained in the absence of concomitant infection * Normal C-reactive protein level at screening * Patients must be red cell transfusion independent for 2 months prior to enrollment * Sexually active women must use an effective method of contraception, or must have undergone clinical documented total hysterectomy and/or oophorectomy, or tubal ligation or be postmenopausal (defined as amenorrhea for at least 12 months) * Written informed consent by the patient Exclusion * Chronic hepatic GVHD with serum total bilirubin over 2 mg/dL * Known hypersensitivity to deferasirox * Serum creatinine above the upper limit of normal * AST or ALT \> 200 U/L during screening * Clinical or laboratory evidence of active Hepatitis B or Hepatitis C (HBsAg in the absence of HBsAb OR HCV Ab positive with HCV RNA positive and ALT above the normal range) * History of HIV positive test result (ELISA or Western blot) * History of drug or alcohol abuse within the 12 months prior to enrollment * ECOG Performance Status \> 2 * Patients with a diagnosis of or history of clinically relevant ocular toxicity related to iron …